Official line from the company:
"Paradigm is aware of the study being conducted by Professor Hunter who is a rheumatology clinician researcher at the University of Sydney. The study will be using an Oral Formulation of PPS therefore does not impact Paradigm’s Patents."
Mozz's thoughts:Ok in regards to this one, it's a study that's being done by an independent researcher...they are just using Elmiron so in other words, the oral dose...You and I know the bio-availability (5%) so not sure why they are bothering but maybe there will be some low level efficacy that will come out of it, it has nothing to do with us (PAR) OR Bene. We are not involved whatsoever. It isn't breaching any patents we have.
research reports and media, page-548
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |